<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785356</url>
  </required_header>
  <id_info>
    <org_study_id>ZPU-302</org_study_id>
    <nct_id>NCT00785356</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids</brief_title>
  <official_title>A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be randomly assigned to one of 3 treatment groups and receive 325 mg (65 mg
      elemental iron) iron supplements twice daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible female subjects will be randomly assigned to one of the three treatment groups.
      Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily
      during study drug treatment. The study duration is approximately six months, which is
      comprised of a 4 - 6 week screening period, a three-month drug treatment period, and a
      one-month follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Repros stopped the study for safety and FDA put the study on hold for safety.
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Comparison Between the 50 mg Proellex® Dose Level and Placebo in the Change in Hemoglobin From Baseline to 3 Months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>25 mg Proellex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 25 mg</intervention_name>
    <description>Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months</description>
    <arm_group_label>25 mg Proellex</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 50 mg</intervention_name>
    <description>Proellex 50 mg, 2 - 25 mg capsules daily for 3 months</description>
    <arm_group_label>Proellex 50 mg</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules daily for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
    <other_name>Dummy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and
             39, inclusive;

          -  Anemic, defined as hemoglobin levels less than or equal to 10.5 g/dL and uterine
             fibroid-associated symptoms indicated by a history of excessive menstrual bleeding;

          -  Surgical interventions for uterine fibroids (e.g. hysterectomy or myomectomy) planned
             or anticipated after the study;

          -  Willing to comply with all study procedures, including the endometrial biopsies and
             blood draws for all visits, including Follow-up Visits

        Exclusion Criteria:

          -  Post-menopausal women or women likely to become post-menopausal during the study,
             defined as one or more of the following:

               -  Six months or more (immediately prior to Screening Visit) without a menstrual
                  period, or

               -  Prior hysterectomy, or

               -  Prior bilateral oophorectomy (unilateral oophorectomy is not exclusionary if
                  regular menstruation is occurring);

          -  Females who have undergone a uterine arterial embolization, or endometrial ablation
             therapy (previous myomectomy is acceptable) for any cause;

          -  Documented endometriosis or active pelvic inflammatory disease (PID);

          -  Having a diagnosis, or suspected diagnosis, of carcinoma of the breast or reproductive
             organs;

          -  Known active infection with HIV, Hepatitis A, B or C, Gonorrhea, or Chlamydia;

          -  Use of prohibited concomitant medications:

               1. Depo-Provera use must cease ten months prior to first dose of study drug, or

               2. GnRH agonists use (e.g. Lupron Depot) must cease six months prior to first dose
                  of study drug, or

               3. Oral contraceptive or other hormonal treatments use must cease for 30 days prior
                  to the start of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre van As, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Perinatal del Estado de Mexico del ISEM</name>
      <address>
        <city>Toluca</city>
        <state>Estado de Mexico C.P.</state>
        <zip>50120</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comité para la Prevención de la Osteoporosis COMOP</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalario Nuevo Sanatorio Durango</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Perinatología &quot;Isidro Espinosa de los Reyes&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>Federal District</state>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Fe</name>
      <address>
        <city>San Miguel de Allende</city>
        <state>Gto</state>
        <zip>37775</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;Dr. José Eleuterio González&quot; Facultad de Medicina de la Universidad Autónoma de Nuevo León (UANL)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIRC (Monterrey International Research Center)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine fibroids</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Groups</title>
          <description>Proellex 25 mg, Proellex 50 mg, 1placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study prematurely terminated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study prematurely terminated</population>
      <group_list>
        <group group_id="B1">
          <title>25 mg Proellex</title>
          <description>Proellex 25 mg: Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Proellex 50 mg</title>
          <description>Proellex 50 mg: Proellex 50 mg, 2 - 25 mg capsules daily for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Placebo, 2 capsules daily for 3 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Comparison Between the 50 mg Proellex® Dose Level and Placebo in the Change in Hemoglobin From Baseline to 3 Months.</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 mg Proellex</title>
            <description>Proellex 25 mg: Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Proellex 50 mg</title>
            <description>Proellex 50 mg: Proellex 50 mg, 2 - 25 mg capsules daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Placebo, 2 capsules daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Comparison Between the 50 mg Proellex® Dose Level and Placebo in the Change in Hemoglobin From Baseline to 3 Months.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events data is available.</desc>
      <group_list>
        <group group_id="E1">
          <title>25 mg Proellex</title>
          <description>Proellex 25 mg: Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Proellex 50 mg</title>
          <description>Proellex 50 mg: Proellex 50 mg, 2 - 25 mg capsules daily for 3 months</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Placebo, 2 capsules daily for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

